Insider buying last 90 days
No open-market insider purchases were filed for MBX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every MBX insider filing, plotted on the chart in Gekko.Open MBX in Gekko
NASDAQ: MBX
MBX Biosciences (MBX) Stock Analysis & Forecast
Oct 12 close
$52.02−1.22 (−2.3%)
Gekko Brief
Oct 12 closeMBX Biosciences closed at $52.02 on 12 October 2026, -2.3% on the day. The price sits between the 50-day ($62.16) and 200-day ($44.23) moving averages, inside a 52-week range of $12.94 to $72.64. The GekkoIndex reads 69.3, in the Accumulation zone, up 7.5 points over five sessions. Gekko Fair Value is $68.90, so the price is 24.5% below it.
The next earnings report is due on 5 November 2026, 24 days away. Over the last 8 reports the company beat the earnings estimate 5 times, with an average move of 8.2% across the report.
8 firms rate the stock: 8 buy, 0 hold and 0 sell, with a consensus target of $94.30. A typical daily move is about 7%, and a typical 20-day move about 15.7%. On the swing-trade checklist, 2 items read supportive and 1 reads as a headwind (earnings risk).
A plain summary of the figures as of the Oct 12, 2026 close.
MBX Biosciences price vs fair value
Close $52.02200-day averageGekko Fair Value $68.90
MBX Biosciences quick facts
- Market cap
- $2.48B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$2.31
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 0.10
- Volume
- 991,552 avg 611,328
- 1-year return
- +228.0%
- Typical daily move
- ±7%
- Typical 20-day move
- ±15.7%
- 50-day average
- $62.16
- 200-day average
- $44.23
- Next earnings
- Nov 5
- Shares outstanding
- 48.16M
MBX Biosciences swing-trade checklist
MBX Biosciences scores 2 supportive, 1 mixed and 1 headwind across the 4 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $52.02 sits between the 50-day ($62.16) and 200-day ($44.23) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
69.3, Accumulation
Reading 69.3 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
24.5% below
Price is 24.5% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityno data
No data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
MBX Biosciences stock chart and price history
MBX Biosciences closed at $52.02 on Oct 12, 2026, +228.0% over the past year, inside a 52-week range of $12.94 to $72.64.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −11.9%
- 3 months
- −8.1%
- 6 months
- +58.5%
- 1 year
- +228.0%
The full MBX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open MBX in Gekko
Follow MBX Biosciences through every session
Put MBX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track MBX in GekkoFree for 7 days. No credit card required.
About MBX Biosciences
MBX Biosciences works on peptide-based drugs aimed at hormone and metabolic disorders, and has not yet brought a product to market. Its furthest-along candidate, MBX 2109, is a prodrug form of parathyroid hormone being tested in Phase 2 trials as a long-acting replacement therapy for people with chronic hypoparathyroidism. The company is also known for pursuing treatments that target metabolic hormone pathways more broadly.
Beyond its lead program, the company is testing MBX 1416, a long-acting compound that blocks GLP-1 receptors, in Phase 1 trials meant to address low blood sugar that can persist after bariatric surgery. A third candidate, MBX 4291, is still in the studies required before human trials can begin; it is designed to act on both GLP-1 and GIP receptors together and is intended for obesity and related conditions. Its pipeline therefore spans early to mid-stage clinical work rather than any approved or marketed treatment.
MBX Biosciences was founded in 2018 and is based in Carmel, Indiana. Its shares are listed on the NASDAQ under the ticker MBX.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- mbxbio.com
MBX Biosciences GekkoIndex: the smart money zone
MBX Biosciences’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 69.3, in the Accumulation zone, up 7.5 points over five sessions.
69.3Accumulation
Up 7.5 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 35 | +6.5% | +19.6% | ||
| Accumulation (current zone) | 161 | +3.6% | +7.4% | ||
| Neutral | 284 | +0.3% | +5.4% | ||
| Distribution | 34 | +3.6% | +13.8% | ||
| Selling | 1 | Too few readings yet | |||
Average MBX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the MBX price, zone by zone.Track MBX in Gekko
Is MBX Biosciences stock overvalued? Gekko Fair Value
MBX Biosciences trades 24.5% below Gekko Fair Value of $68.90, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what MBX Biosciences shares are worth, recalculated every trading day.
$68.90
Gekko Fair Value, Oct 10, 2026
24.5% Undervalued
At the end of Aug 2026 the price was 22.1% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open MBX in Gekko
MBX Biosciences insider and Congress trading
No open-market insider purchases were filed for MBX Biosciences, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in MBX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for MBX, plotted on the chart in Gekko.Open MBX in Gekko
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds MBX.
0added0opened1trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
MBX Biosciences earnings: next date and track record
MBX Biosciences reports on Nov 5, 2026 (24 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 5, 2026
24 days away
- EPS estimate
- −$0.83
5 of 8reports beat the EPS estimate
±8.2%average move across the report
5 of 7reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$0.78 est −$0.63 | — | +0.5% |
| May 7, 2026 | −$0.51 est −$0.58 | — | +27.6% |
| Mar 12, 2026 | −$0.49 est −$0.60 | — | −3.2% |
| Nov 6, 2025 | −$0.63 est −$0.73 | — | +13.4% |
| Aug 7, 2025 | −$0.58 est −$0.77 | — | +4.2% |
| May 12, 2025 | −$0.71 est −$0.81 | — | −7.6% |
| Nov 7, 2024 | −$2.78 est −$2.72 | — | +0.7% |
| Aug 23, 2024 | −$11.47 est $0.00 | — | — |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
MBX Biosciences stock forecast and analyst price targets
Analysts’ average 12-month price target for MBX Biosciences is $94.30, +81.3% from the last close, from 8 firms rating the stock in the last 90 days.
$94.30consensus 12-month target, +81.3% from the last close
Now $52.02Avg $94.30
Low $84High $150
Each firm’s latest rating in the last 90 days: 8 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 12 | Guggenheim | $150 | +188.4% |
| Oct 12 | Stifel Nicolaus | $84 | +61.5% |
| Oct 2 | Guggenheim | $150 | +188.4% |
| Aug 21 | J.P. Morgan | $88 | +69.2% |
| Aug 11 | Stifel Nicolaus | $70 | +34.6% |
+7.4%average 20-day move after past Accumulation readings
±7%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
MBX Biosciences market cap and key statistics
MBX Biosciences’s market cap is $2.48B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $2.48B
- EPS, TTM
- −$2.31
- Gekko Fair Value
- $68.90
Trading
- Volume
- 991,552
- Avg volume, 20 days
- 611,328
- 52-week high
- $72.64
- 52-week low
- $12.94
- Shares outstanding
- 48.16M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -33.2%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.10
- Typical daily move
- ±7%
- Typical 20-day move
- ±15.7%
MBX Biosciences stock news this week
Coverage of MBX Biosciences this week reads positive: 3 positive, 0 neutral and 0 negative headlines.
- MBX Biosciences (NASDAQ:MBX) Given New $84.00 Price Target at Stifel NicolausMarketBeat, Oct 12
- Stifel raises MBX Biosciences price target to $84 on obesity drug dataInvesting.com, Oct 12
- Is MBX Biosciences (MBX) Still Undervalued After Its Pullback From A Strong 1 Year Run?Yahoo Finance, Oct 10
MBX Biosciences peers
MBX Biosciences’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
MBX Biosciences stock FAQ
What is MBX Biosciences’s market cap?
MBX Biosciences’s market cap is $2.48B at the Oct 12, 2026 close of $52.02, with 48.16M shares outstanding.
What is the MBX Biosciences stock forecast?
The consensus analyst 12-month price target for MBX Biosciences is $94.30, +81.3% from the last close. Of the 8 firms that rated the stock in the last 90 days, 8 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is MBX Biosciences stock overvalued or undervalued?
On Gekko’s estimate MBX Biosciences is undervalued: the Oct 12, 2026 close of $52.02 is 24.5% below Gekko Fair Value of $68.90. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does MBX Biosciences report earnings next?
MBX Biosciences is expected to report on Nov 5, 2026 (24 days away). Analysts expect earnings of −$0.83 per share. MBX Biosciences beat the earnings estimate in 5 of its last 8 reports, moving 8.2% on average across the report.
What is MBX Biosciences’s 52-week high and low?
MBX Biosciences’s 52-week high is $72.64 and its 52-week low is $12.94; it closed at $52.02 on Oct 12, 2026, +228.0% over the past year.
Is MBX Biosciences stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 4 items with data read as supportive (gekkoindex and fair value), 1 as mixed (trend) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See MBX Biosciences the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.